RCS - Diaceutics PLC - Diaceutics forms landmark industry Forum

DiaceuticsAnnouncement

19/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240319:nRSS3232Ha&default-theme=true

RNS Number : 3232H  Diaceutics PLC  19 March 2024

RNS Reach

 

Diaceutics PLC

 

Diaceutics forms landmark industry Forum to address the economic barriers
preventing patient access to life-changing precision medicines

 

Belfast and London, 19 March 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry,
announces the establishment of its Precision Medicine Practice Gaps Economic,
Policy and Operational Solutions Forum, aiming to urgently address the
specific economic gaps limiting the advancement of precision medicine and to
enable every patient to get the treatment they deserve.

Co-chaired by Susanne Munksted, Chief Precision Medicine Officer at
Diaceutics, and Denny Van Liew, Board Member Emeritus at the Precision
Medicine Coalition (PMC) and veteran Solution Architect and Life Sciences
Senior Advisor at Red Nucleus, the Forum is composed of leading experts in
precision medicine across multiple stakeholders, each bringing extensive
experience and insights from their careers.

 

The solutions and recommendations proposed by the Forum will be shared and
opened for discussion at a virtual global summit on May 1(st), providing a
unique opportunity for all members of the precision medicine community to
contribute to the culminating white paper recommendations and play a role in
shaping the future of precision medicine.

 

Susanne Munksted, Chief Precision Medicine Officer of Diaceutics, commented,
"From our long-standing central position within the precision medicine
industry, connecting pharma, labs and patients, we have amassed a wealth of
data. Our analysis of this data has enabled us to identify 7 practice gaps
that are holding back the uptake of precision medicine, and running through
all of them is an economic thread. The industry collectively needs to make
precision medicine more economically viable, to ensure that every patient gets
the treatment they deserve. The Forum brings together key voices in the
industry to collaborate on a best way forward, for all."

 

Background to the Forum's formation

In 2022, research undertaken by Diaceutics and The Personalized Medicine
Coalition (PMC) and published in The Journal of Clinical Oncology Precision
Oncology (JCO) highlighted that 64.4% of advanced non-small cell lung cancer
patients in the US may not receive the best treatment for their disease and
identified 7 Clinical Practice Gaps limiting patient access to precision
medicine.

Daryl Pritchard, Precision Medicine Coalition's Senior Vice President, Science
Policy, commented, "The technologies, clinical practices, and financial
incentives needed to successfully deliver high-quality health care in the era
of personalised medicine differ substantially in comparison to what was needed
during decades characterised by less sophisticated approaches."

 

"If the economic challenges providers face in adopting personalised medicine
are left unaddressed, patients will suffer as high-value personalised medicine
technologies will needlessly be left on the shelf."

 

Sarah Hersey, Vice President of Precision Medicine at Bristol-Myers Squibb and
member of the Forum, stated, "This forum will serve as a healthy discourse to
address the root complexities surrounding precision medicine and economic
barriers. Together, the precision medicine community can identify possible
solutions to close the clinical care gaps and help increase access to
effective treatments for patients in need."

"Those of us operating in precision medicine have been aware of the stealthy
influence which economics have had on patient testing in precision medicine.
This has not always been for the better. Revisiting the 2022 Clinical Practice
Gaps research with a deeper focus on the economic barriers preventing patients
receiving optimized targeted treatments has brought insightful discussion
amongst the Forum members. It was rewarding to see how informed we all were on
the real-world issues and how aligned we could be on the potential solutions
to positively impact patients."

 

Denny Van Liew, Board Member Emeritus at the PMC and veteran Solution
Architect and Life Sciences Senior Advisor at Red Nucleus, adds, "The passion
amongst the Forum members demonstrates there is ambition to overcome the
economic challenges which exist and support the wider precision medicine
industry by providing practical recommendations and guidance on future policy
development. I welcome everyone across precision medicine to join the
discussion in May and to offer their input into this important paper."

 

Enquiries:

 

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Susanne Munksted, Chief Precision Medicine Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison, Nick Harland, Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde, Kinvara Verdon, Kieran Breheny         diaceutics@almastrategic.com

 

About the virtual summit

Attendees at the summit will have exclusive access to a virtual conference
hall hosting relevant economic papers analysed by Forum members along with
gaining first access to a white paper summary of the Forum's recommendations.
The summit is free to attend and will consist of expert panel discussions with
Forum members and the opportunity for direct Q&A and voting on key
recommendations.

 

Forum Members

 Forum Member            Organization
 Amy Gorman             Global Precision Medicine & Diagnostics Commercial Leader, AbbVie
 Brenda Yanak           Founder, Clinical Transformation Partners
 Cecilia Schott         VP, Head of Global Precision Diagnostics, Novartis
 Dawn Cardeiro          Director of Precision Medicine, Point32 Health
 Dr Daryl Pritchard     Senior Vice President of Science Policy, Personalized Medicine Coalition
 Denny Van Liew         Life Sciences Senior Advisor and Solution Architect, Red Nucleus
 Prof. Gerardine Doyle  Full Professor of Accounting, University College Dublin

                        Recently served a five-year term as Director of Michael Smurfit Graduate
                        Business School

                        Visiting Scholar, Harvard Business School
 Dr Kamala Maddali      President, Health Collaborations, USA
 Prof. Mark Lawler      Chair in Translational Cancer Genomics, Queen's University Belfast
 Peter Keeling          Founder, Diaceutics
 Dr Pranil Chandra      Senior Vice President and Chief Genomics Officer, Pathgroup
 Sarah Hersey           Vice President Head of Precision Medicine, BMS
 Sibylle Lenz           Head of Precision Medicine and Vice President, Merck & Co. Inc
 Susanne Munksted       Chief Precision Medicine Officer, Diaceutics
 Terri Conneran         Terri Conneran

                        Founder, KRAS Kickers

                        Survivor KRAS G12D lung cancer

 

 

About Diaceutics

 

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

 We provide the world's leading pharma and biotech companies with an
end-to-end commercialisation solution for precision medicines through data
analytics, scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®

 

 

 

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADBGDXXXBDGSI